SCHEMBL2198570

SCHEMBL2198570

Cc1cc(F)ccc1Nc1ccc(C(=O)c2cc(C(=O)N3CCN(C)CC3)ccc2C)c(Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.62
MAPK13 O15264 6/20 0.62
MAPK12 P53778 6/20 0.62
MAPK11 Q15759 6/20 0.62
EPHX2 P34913 1/20 0.45
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
P2RX7 Q99572 1/20 0.41
NTRK1 P04629 2/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPY2R P49146 1/20 0.40
CCNT1 O60563 1/20 0.40
CCNE1 P24864 1/20 0.40
CDK2 P24941 1/20 0.40
CDK9 P50750 1/20 0.40
AVPR2 P30518 1/20 0.40
AVPR1A P37288 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2200850 0.90 MAPK14 (0.61) MAPK14MAPK13MAPK12MAPK11EPHX2
SCHEMBL27655256 0.90 MAPK14 (0.49) MAPK14MAPK13MAPK12MAPK11EPHX2
SCHEMBL6022997 0.88 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK11
SCHEMBL2200568 0.84 MAPK14 (0.63) MAPK14MAPK13MAPK12MAPK11EPHX2
SCHEMBL27633942 0.81 MAPK14 (0.49) MAPK14MAPK13MAPK12MAPK11EPHX2
SCHEMBL2856599 0.78 MAPK14 (0.74) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL2198608 0.78 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11AVPR2
SCHEMBL2199941 0.78 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL2199211 0.78 MAPK13 (0.63) MAPK14MAPK13MAPK12MAPK11KMT2A
SCHEMBL2198601 0.78 MAPK13 (0.63) MAPK14MAPK13MAPK12MAPK11MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006528597-A 2006-12-21 JP claimed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US claimed
EP-1658263-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS Leo Pharma A/S (DK) 2006-05-24 EP claimed
WO-2005009940-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA A/S (DK) 2005-02-03 WO claimed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US disclosed
EP-1658263-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS Leo Pharma A/S (DK) 2006-05-24 EP disclosed
WO-2005009940-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA A/S (DK) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166990-A1 Novel aminobenzophenone compounds NFKBIA, UACA, ALDH7A1 MAPK14 697/4885MAPK13 1063/4885MAPK12 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.